EPA, not DHA, prevents fibrosis in pressure overload-induced heart failure: potential role of free fatty acid receptor 4

Overview of attention for article published in Journal of Lipid Research, October 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 6 news outlets
twitter: 4 X users

facebook: 1 Facebook page

Readers on

mendeley: 49 Mendeley

So far, Altmetric has seen 6 news stories from 6 outlets.

HLS THERAPEUTICS : Supports Trial to Investigate the Effects of Vascepa against COVID-19

MarketScreener, 22 May 2020

TORONTO - HLS Therapeutics Inc. ('HLS' or the 'Company') (TSX: HLS), a specialty pharmaceutical company focusing on central…

HLS Therapeutics Supports Trial to Investigate the Effects of Vascepa® (Icosapent Ethyl) against COVID-19

Ticker Tech, 21 May 2020

TORONTO, May 21, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company…

HLS Therapeutics Supports Trial to Investigate the Effects of Vascepa ® (Icosapent Ethyl) against COVID-19

Stockwatch, 21 May 2020

Canada NewsWire TORONTO, May 21, 2020 TORONTO, May 21, 2020 /CNW/ - HLS Therapeutics Inc.

HLS Therapeutics Supports Trial to Investigate the Effects of Vascepa® (Icosapent Ethyl) against COVID-19

Benzinga, 21 May 2020

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:), a specialty pharmaceutical company focusing on central nervous…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 2 additional news stories.